Benjamin Rengstl

Benjamin Rengstl

Company: BioNTech Cell & Gene Therapies & BioNTech SE

Job title: Director Immunoreceptor Therapy & Medical Expert Clinical Development


Workshop E: BNT211: A Phase 1/11 Trial to Evaluate Safety & Efficacy of CLDN6 CAR-T & CARVas Based In Vivo Expansion to Improve Treatment of Patients with CLDN6+ Advanced Solid Tumours 12:00 pm

Update on preliminary data from Ph1 dose escalation for CLDN6 CAR-T monotherapy and combination with CARVac Introduction of new manufacturing process Insights into exploratory biomarker programmeRead more

day: Workshop – Track B – Afternoon

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.